argenx: Phase 3 ALKIVIA data show lasting gains for efgartigimod in myositis
The Phase 3 ALKIVIA study of efgartigimod met its primary and key secondary endpoints in IMNM and DM patients, according to Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
argenx SE presented Phase 3 ALKIVIA study data at the ACR Convergence 2026 meeting, according to Reuters. Efgartigimod produced rapid and sustained improvement in autoimmune myositis. The study met its primary and key secondary endpoints in the combined IMNM and DM population. It also showed a statistically significant benefit in IMNM. The company plans to submit an sBLA for efgartigimod in IMNM to the FDA by the end of 2026.
why it matters
Two points matter for investors: a successful Phase 3 study lowers regulatory risk and opens a path to broader use of the drug. The news mainly concerns one company's shares, so the impact on the wider market is limited.
market impact
argenx shares: positive Phase 3 data support expectations for a broader label for the drug
- argenx SE shares pressure up — positive Phase 3 data strengthen the outlook for efgartigimod
tags
instruments
sources
- Argenx Presents Phase 3 ALKIVIA Data At Acr Convergence 2026 Showing Rapid And Sustained Improvement With Efgartigimod In Autoimmune Myositis — Reuters, 7 November 2026 at 15:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗